Dr. Clemens Günther received his diploma in biology and doctorate for natural sciences from the Free University, Berlin-Germany.
From 1990 to 2006 he started his professional career at Schering AG, Berlin-Germany.
From 2007 to 2013, Dr. Clemens Günther was Director and Head of Global Preclinical Development at Intendis GmbH, branded later-on as Bayer Dermatology. In this position, he was responsible for Nonclinical Safety for the marketed product portfolio of Bayer Dermatology as well as the global preclinical development strategy including human DMPK for development and life cycle management projects.
Since integration of Intendis into Bayer in 2013, he became Director Nonclinical Safety Consumer Care within the Division of Bayer Pharmaceuticals.
Meanwhile Dr. Clemens Günther has gained over 25 years experience in nonclinical safety. He has been involved in nonclinical development and regulatory toxicology of small molecules, biologics, medical devices and drug device combination products.